Indicators
Indicators
Value
Direction
MACD(12,26,9)
3.034
Buy
RSI(14)
57.536
Neutral
STOCH(KDJ)(9,3,3)
81.176
Neutral
ATR(14)
8.299
Low Volatility
CCI(14)
113.297
Buy
Williams %R
13.338
Overbought
TRIX(12,20)
0.029
Sell
StochRSI(14)
55.839
Sell
Search
Beigene Ltd
ONCAdd to Watchlist
310.980USD
-4.090-1.30%
Market hours （ET）Quotes delayed by 15 min
31.80BMarket Cap
66.62P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Beigene Ltd
Currency: USD Updated: 2026-05-12Key Insights
Beigene Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 10 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 405.33.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beigene Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Beigene Ltd Highlights
StrengthsRisks
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 5.34B.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 117.30% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 67.49, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 40.42M shares, increasing 4.63% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 1.51K shares of this stock.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
405.335
Target Price
+29.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-12The current financial score of Beigene Ltd is 9.47, ranking 1 out of 383 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.51B, representing a year-over-year increase of 35.46%, while its net profit experienced a year-over-year increase of 17802.13%.
Score
Financials
9.56
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.78
Beigene Ltd's Company Valuation
Currency: USD Updated: 2026-05-12The current valuation score of Beigene Ltd is 7.49, ranking 108 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is 67.49, which is 809.34% below the recent high of 613.74 and 409.70% above the recent low of -209.02.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 10/383
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-12The current earnings forecast score of Beigene Ltd is 8.31, ranking 137 out of 383 in the Biotechnology & Medical Research industry. The average price target is 396.00, with a high of 448.00 and a low of 250.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
405.335
Target Price
+29.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Kymera Therapeutics Inc
KYMR
24
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-12The current price momentum score of Beigene Ltd is 8.57, ranking 79 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 332.46 and the support level at 293.61, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
313.652
Sell
MA10
304.282
Buy
MA20
307.389
Buy
MA50
299.649
Buy
MA100
317.671
Sell
MA200
321.080
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-12The current institutional shareholding score of Beigene Ltd is 3.00, ranking 193 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 36.84%, representing a quarter-over-quarter increase of 17.61%. The largest institutional shareholder is PRIMECAP Management, holding a total of 4.98M shares, representing 4.54% of shares outstanding, with 1.63% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Amgen Inc
Baker Bros. Advisors LP
Capital International Investors
Fidelity Management & Research Company LLC
HHLR Advisors, Ltd.
Temasek Holdings Pte. Ltd.
T. Rowe Price International Ltd
BlackRock Institutional Trust Company, N.A.
1
2
Risk Assessment
Currency: USD Updated: 2026-05-12The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Beigene Ltd is 7.02, ranking 18 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.51
VaR
+5.19%
240-Day Maximum Drawdown
+27.22%
240-Day Volatility
+44.82%
Return
Best Daily Return
60 days
+5.32%
120 days
+5.47%
5 years
+25.12%
Worst Daily Return
60 days
-8.48%
120 days
-8.48%
5 years
-15.71%
Sharpe Ratio
60 days
-0.83
120 days
-0.68
5 years
+0.28
Risk Assessment
Maximum Drawdown
240 days
+27.22%
3 years
+42.47%
5 years
+69.96%
Return-to-Drawdown Ratio
240 days
+1.14
3 years
+0.59
5 years
-0.00
Skewness
240 days
+0.15
3 years
+0.19
5 years
+0.54
Volatility
Realised Volatility
240 days
+44.82%
5 years
+58.95%
Standardised True Range
240 days
+3.37%
5 years
+3.21%
Downside Risk-Adjusted Return
120 days
-101.82%
240 days
-101.82%
Maximum Daily Upside Volatility
60 days
+32.22%
Maximum Daily Downside Volatility
60 days
+33.56%
Liquidity
Average Turnover Rate
60 days
+0.02%
120 days
+0.02%
5 years
--
Turnover Deviation
20 days
-34.50%
60 days
-30.85%
120 days
-23.63%
Peer Comparison
Biotechnology & Medical Research
Beigene Ltd
ONC
7.87 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
